Interferon treatment in patients with hypereosinophilia

    3 Citations (Scopus)


    Most of the primary conditions with eosinophilia have now been characterized by clonality in 2008 by the WHO classification, which thereby provide a basis for separation of patients who may benefit a targeted therapy, i.e. by tyrosine kinase inhibition--and who may not. Treatment with interferon-α was introduced some 20 years ago and still has a role in subsets of patients, which is evident from this review of casuistic reports of treatment. However, controlled, randomized, prospective, clinical trials in multi-center studies are needed to clarify dosages, monitoring, prognosis and perhaps combination therapies with interferon-α, i.e. antibodies or other immune suppressants, in the rare patients with primary eosinophilia.
    Original languageEnglish
    JournalCurrent Drug Targets
    Issue number3
    Pages (from-to)429-32
    Number of pages4
    Publication statusPublished - 2011


    • Eosinophilia
    • Eosinophils
    • Humans
    • Immunologic Factors
    • Interferon-alpha
    • Leukopoiesis


    Dive into the research topics of 'Interferon treatment in patients with hypereosinophilia'. Together they form a unique fingerprint.

    Cite this